Breaking
New Market Perspective
Author

admin

Browsing
Investing

North Shore Closes $1.4 Million Non-brokered Private Placement & Enters Into Rio Puerco Option Agreement

North Shore Uranium Ltd. (TSXV:NSU) (‘North Shore‘ or the ‘Company‘) is pleased to announce that it has closed the non-brokered private placement as previously announced on August 7, 2025 (the ‘Offering‘), through the issuance of 24,055,000 non-flow-through units (the ‘NFT Units‘) at a purchase price of $0.05 per NFT Unit and 3,034,922 flow-through units (the ‘FT Units‘) at a purchase price of $0.065 per FT Unit for total aggregate gross proceeds of $1,400,020.

The Company also announces it has entered into a definitive option agreement (the ‘Option Agreement‘) with Resurrection Mining LLC (‘Resurrection‘), an arm’s length party, to acquire up to 87.5% of the Rio Puerco uranium project (‘Rio Puerco‘ or the ‘Project‘) located in northwestern New Mexico (the ‘Transaction‘). The signing of a binding term sheet (the ‘Term Sheet‘) was announced on June 24, 2025.

Brooke Clements, President and CEO of North Shore stated: ‘This is a very exciting milestone for North Shore. The private placement was significantly oversubscribed and we would like to thank our existing shareholders and new shareholders for their support. The Rio Puerco project in New Mexico hosts a significant historical uranium resource and offers us exposure to a uranium project in the USA with excellent upside, at a time when the US government is increasing its support for the nuclear power and uranium mining sectors. The Company plans to work towards confirming and expanding upon previous work at Rio Puerco while further assessing the potential for in-situ uranium recovery. North Shore now has uranium exposure in two North American jurisdictions that have seen significant uranium production, the Grants Uranium District in New Mexico and the Athabasca Basin in Saskatchewan, at a time when the world is moving to increase its reliance on nuclear power.’

$1.4 Million Private Placement

Each NFT Unit consists of one non-flow-through common share and one-half of one share purchase warrant (each whole share purchase warrant, a ‘Warrant‘). Each FT Unit consists of one flow-through common share and one-half of one Warrant. Each Warrant entitles the holder to purchase one non-flow through common share (each a ‘Warrant Share‘) at a price of $0.10 per Warrant Share for a period of two years from the date of closing the Offering.

The net proceeds of the Offering will be used to complete the Transaction, exploration of the Project, continued exploration of the Company’s Saskatchewan uranium properties, the costs of the Offering and for general working capital.

In connection with the Offering, the Company paid cash finder’s fees of $13,500 and issued 228,462 non-transferable finder’s warrants to certain arm’s length finders. The non-transferable finder’s warrant is exercisable to acquire one common share of the Company at a price of $0.10 per share for a period of two years from the date of closing the Offering.

All securities issued in connection with the Offering are subject to a four-month and one-day hold period from the date of closing the Offering. The Offering is subject to the final approval of the TSX Venture Exchange (the ‘Exchange‘).

The completion of the Offering satisfied a closing requirement of the Transaction which required the Company to complete a financing raising a minimum of $750,000.

Insider Participation

Brooke Clements, Director, President and CEO of the Company, James Arthur, a Director of the Company, and Doris Meyer, a Director of the Company, participated in the Offering. These purchases constitute as related party transactions pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). There has not been a material change in the percentage of the outstanding securities of the Company that are individually or beneficially owned by Messrs. Clements or Arthur, or Ms. Meyer as a result of their participation in the Offering. The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the participation of the insiders in the Offering in reliance of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the fair market value of the insider participation does not exceed 25% of the Company’s market capitalization as determined in accordance with MI 61-101.

The Company obtained approval by the board of directors of the Company of the Offering, with Messrs. Clements and Arthur, and Ms. Meyer declaring and abstaining from voting on the resolutions approving the Offering with respect to their participation in the Offering. No materially contrary view or abstention was expressed or made by any director of the Company in relation thereto.

Rio Puerco Option Agreement

Upon closing of the Offering, and thereby satisfying the financing requirement of the Transaction, the Company entered into the Option Agreement with Resurrection to acquire up to 87.5% of the Project. The terms of the Option Agreement are substantively the same as the terms of the Term Sheet which was announced on June 24, 2025.

Pursuant to the Option Agreement, the Company paid Resurrection a cash payment of $125,000 and issued Resurrection 7,483,000 common shares in the capital of the Company (the ‘Common Shares‘) at a deemed issue price of $0.05, so that Resurrection holds 9.99% of the Common Shares post-Offering, satisfying the Company’s Milestone 1 obligations. The 7,483,000 Common Shares issued will bear a legend restricting trading for a period of two years from the date of issuance.

The remaining milestones and key terms of the Option Agreement are as follows:

  • Milestone 2, to earn a 40% interest in the Project: on or before 18 months after completion of the Transaction, a $250,000 payment in cash or Common Shares, at the option of North Shore, and $750,000 in exploration expenditures.
  • Milestone 3, to earn an aggregate 65% interest in the Project: on or before 36 months after completion of the Transaction, a $375,000 payment in cash or Common Shares, at the option of North Shore, and $1,000,000 in additional exploration expenditures.
  • Milestone 4, to earn an aggregate 87.5% interest in the Project: on or before 60 months after completion of the Transaction, a $500,000 payment in cash or Common Shares, at the option of North Shore, and $1,500,000 in additional exploration expenditures.
  • North Shore may elect to not continue to sole-fund exploration expenditures at any time after earning a 40% interest in Rio Puerco at which time North Shore and Resurrection will enter into a joint venture agreement to govern the funding of Rio Puerco on a proportional basis.
  • Bonus payments: For the 78-month period after completion of the Transaction, North Shore will pay Resurrection $100,000 or issue Common Shares of the same value as a bonus (the ‘Bonus Payment‘) for each million lbs. of uranium estimated in current resources defined by the Company above 5 million and up to 20 million lbs. in accordance with NI 43-101 standards, if and when such resources are defined.
  • Other terms: Resurrection shall have a participation right to maintain its 9.99% interest in the Common Shares of North Shore for 5 years from completion of the Transaction and the right, but not the obligation, to appoint one nominee to the North Shore Board of Directors. All share issuances will be subject to Canadian and US securities law and will be priced in accordance with Exchange policies.

The Transaction constituted an ‘Expedited Acquisition’ in accordance with Exchange policies. All Common Shares issued and issuable under the Option Agreement will be issued with a restrictive period of four months and one day. The minimum deemed share price of any Common Share issuance is $0.05 and will be priced in accordance with the Exchange policies. There were no finder’s fees payable in connection with the Option Agreement.

Technical disclosure on the Property can be found in the Company’s news release dated June 24, 2025.

Caution to US Investors

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements. ‘United States’ and ‘U.S. person’ have the respective meanings assigned in Regulation S under the U.S Securities Act.

ABOUT NORTH SHORE

The nuclear power industry is in growth mode as more nuclear power will be required to meet the world’s ambitious CO2 emission-reduction goals and the needs of new power-intensive technologies like AI. In this environment, new discoveries of economic uranium deposits will be very valuable, especially in established uranium-producing jurisdictions like Saskatchewan and New Mexico. North Shore is well-positioned to become a major force in exploration for economic uranium deposits. The Company is working to achieve this goal by exploring its Falcon and West Bear properties at the eastern margin of the Athabasca Basin in Saskatchewan, expanding its exploration efforts to include the Grants Uranium District in New Mexico and by evaluating other quality opportunities in the United States and Canada to complement its portfolio of uranium properties. North Shore summarized its exploration efforts at its Falcon property in the Company’s May 27, 2025 news release. For more information about the Rio Puerco property, see the Company’s June 24, 2025 news release.

ON BEHALF OF THE BOARD

Brooke Clements,
President, Chief Executive Officer and Director

For further information:
Please contact: Brooke Clements, President, Chief Executive Officer and Director
Telephone: 604.536.2711
Email: b.clements@northshoreuranium.com
www.northshoreuranium.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as ‘plan’, ‘project’, ‘appear’, ‘interpret’, ‘coincident’, ‘potential’, ‘confirm’, ‘suggest’, ‘evaluate’, ‘encourage’, ‘likely’, ‘anomaly’, ‘continuous’ and variations of these words as well as other similar words or statements that certain events or conditions ‘could’, ‘may’, ‘should’, ‘would’ or ‘will’ occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the highly speculative nature of the Property given the early-stage nature of Rio Puerco; the ability of the Company to meet the Milestones; the ability of the Company to acquire up to 87.5% of the Project; the creation of a joint venture between the Company and Resurrection; the Bonus Payment to Resurrection; the actual results of current and planned exploration activities including the potential for the definition of a mineral deposit of potential economic value at the Company’s Falcon property in Saskatchewan and Rio Puerco in New Mexico; that drilling results, geophysical survey results and/or interpretations thereof define potentially mineralized corridors; results from future exploration programs including drilling; interpretation and meaning of completed and future geophysical surveys; conclusions of future economic evaluations; changes in project parameters as plans to continue to be refined; possible variations in grades of mineralization and/or future actual recovery rates; accidents, labour disputes and other risks of the mining industry; the availability of sufficient funding on terms acceptable to the Company to complete the planned work programs; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events or results not to be as anticipated, estimated, or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Source

Click here to connect with North Shore Uranium (TSXV:NSU) to receive an Investor Presentation

This post appeared first on investingnews.com

Keep Reading
Investing

Cobre Limited

Investor Insight

Cobre offers investors a rare combination of district-scale copper-silver discovery potential, near-term development upside through its ISCR-ready Ngami copper project, and a capital-light growth model underpinned by major-partner funding and diversified exposure to critical minerals.

Overview

Cobre (ASX:CBE) is an Australian exploration company unlocking the copper-silver potential of the Kalahari Copper Belt in Botswana, one of the world’s most prospective but underexplored sediment-hosted copper provinces. With approximately 5,348 sq km of land position, the company’s near-term focus is the Ngami copper project (NCP), where a maiden JORC resource at the Comet deposit establishes an initial copper-silver resource with strong in-situ copper recovery (ISCR) development credentials.

Cobre’s project location in the Kalahari Copper Belt

Cobre’s growth strategy balances district-scale discovery potential with development-ready assets, leveraging major-partner funding, including up to AU$40 million (US$25 million) investment from BHP to accelerate exploration at Kitlanya, while concentrating company capital on advancing NCP through technical, environmental and permitting milestones. The company complements its Botswana assets with strategic exposure to high-purity quartz and volcanogenic massive sulphide (VMS) opportunities in Western Australia. This diversified, capital-light approach aims to build shareholder value through discovery, derisking and development optionality.

Company Highlights

  • Dominant land position – ~5,348 sq km across Botswana’s Kalahari Copper Belt (KCB), the second largest tenement package in the districtInvestor
  • Maiden JORC Mineral Resource – Comet deposit (Ngami copper project): 11.5 Mt @ 0.52 percent copper and 11.6 grams per ton (g/t) silver (60.3 kt copper; 4.3 Moz silver), incl. 1.1 Mt indicated @ 0.59 percent copper and 12.8 g/t silver
  • BHP partnership – Eight-year earn-in across Kitlanya East & West, allowing BHP to earn 75 percent by providing up to US$25 million for exploration expenditure, while Cobre retains exposure
  • BHP Xplor cohort – Selected in 2024, securing US$500,000 non-dilutive funding and technical support
  • Multi-jurisdiction exploration portfolio – Botswana (copper-silver), Western Australia (VMS, high-purity quartz)

Key Projects

Ngami Copper Project

The 100 percent owned Ngami copper project is Cobre’s flagship asset and the primary focus of current exploration and technical work. Situated in the Kalahari Copper Belt (KCB), NCP spans multiple licences covering highly prospective sediment-hosted copper-silver targets along basin margins.

Comet Deposit – Maiden JORC Resource

  • Announced in August 2025, the Comet deposit hosts 11.5 Mt @ 0.52 percent copper and 11.6 g/t silver, including 1.1 Mt indicated @ 0.59 percent copper and 12.8 g/t silver, at a 0.2 percent copper cut-off.
  • Contained metal: ~60,300 tonnes copper and 4.3 Moz silver.
  • Mineralisation is predominantly fine-grained chalcocite, an ideal feedstock for hydrometallurgical processing.

In-Situ Copper Recovery Development Potential

ISCR is a low-cost, low-impact method of producing copper by circulating a solution through the orebody underground to dissolve and pump the metal to surface for processing. For Cobre’s Ngami project, ISCR offers the potential to unlock value without the expense and disruption of conventional mining, thanks to favourable geology, high recoveries in test work, and minimal surface disturbance – positioning it as a potentially faster, cleaner and more capital-efficient path to production.

Exploration Upside

Beyond the initial Comet resource, Ngami hosts extensive growth potential with 40 km of mineralised strike and large, defined exploration targets that could significantly expand the resource base. Early drilling at new zones, such as the Cosmos target, has intersected high-grade copper. More than 20 km of prospective contact remains untested, offering multiple opportunities for further discoveries that could enhance scale, mine life and project economics.

Kitlanya East & West

Cobre’s Kitlanya East and West licences, also located in Botswana, involve an eight-year earn-in agreement with BHP. Under the deal, BHP can invest up to US$25 million to earn a 75 percent interest in Kitlanya, allowing the company to leverage a major partner’s technical expertise and funding while retaining exposure to potential tier-one discoveries. Exploration is targeting preserved fold hinge settings along basin margins – geological positions known to host large sediment-hosted copper deposits – using advanced geophysics and seismic techniques to define high-priority drill targets.

Okavango Copper Project

Another Botswana copper asset, the Okavango project is located along strike from MMG’s Zone 5 deposit. Okavango offers 186 km of prospective contact in the northeast Kalahari Copper Belt. Early drilling has intersected multiple zones of anomalous copper and silver mineralisation, and geophysical data shows gravity signatures comparable to those in producing areas, indicating strong potential for significant new discoveries.

Perrinvale Project

In addition to its African portfolio, Cobre holds the Perrinvale project in Western Australia, prospective for both high-grade VMS mineralisation and high-purity quartz (HPQ). The HPQ target has an exploration range of 5.1 to 28.3 Mt grading 99.1 to 99.6 percent SiO₂, positioning it as a potential supplier to critical silicon markets for renewable energy and electronics.

Management Team

Martin Holland – Executive Chairman

Martin Holland is the founder of Cobre and co-founder of multiple ASX-listed companies, including Lithium Power International. He has more than 15 years’ experience in capital markets and resource company leadership, raising more than AU$200 million for exploration.

Adam Wooldridge – Chief Executive Officer

Founding partner and CEO of KML, Adam Woolridge has more than 28 years’ experience in exploration management and target generation in Africa, the Middle East and Europe.

Ross McGowan – Non-executive Director

CEO of Armada Metals and founder of RED Group, Ross McGowan has over 20 years of experience in African exploration, and was part of the Kamoa discovery team.

Michael McNeilly – Non-executive Director

Michael McNeilly, is a corporate financier and CEO of Strata Plc, with experience across multiple listed resource companies.

Michael Addison – Non-executive Director

Michael Addison is the founder of Endocoal, Carabella Resources and Genex Power, with extensive mining and energy development background.

Andrew Sissian – Non-executive Director

Andrew Sissian is co-founder of Cobre and Procon Telematics. He is a corporate and capital markets specialist with a CPA background.

This post appeared first on investingnews.com

Keep Reading
Investing

NVIDIA Delivers Record Quarter as AI Demand Booms, but China Uncertainty Persists

NVIDIA (NASDAQ:NVDA) delivered another blockbuster quarter, reporting record revenue of US$46.7 billion for its second fiscal period as demand for artificial intelligence (AI) infrastructure continues to surge.

The chipmaking giant said sales rose 56 percent from a year earlier and 6 percent from the prior quarter, marking the ninth straight period of year-on-year revenue growth above 50 percent.

Meanwhile, NVIDIA’s net income jumped 59 percent to US$26.42 billion from US$16.6 billion. Its adjusted earnings per share were US$1.05, beating analyst forecasts of US$1.01.

“Blackwell is the AI platform the world has been waiting for, delivering an exceptional generational leap — production of Blackwell Ultra is ramping at full speed, and demand is extraordinary,” said founder and CEO Jensen Huang.

“The AI race is on, and Blackwell is the platform at its center,” he added.

The company’s data center division once again fueled growth as it generated US$41.1 billion in revenue, 56 percent higher than a year ago. Roughly US$33.8 billion of that total came from sales of NVIDIA’s GPUs, while US$7.3 billion was from networking hardware that ties together large AI computing systems.

Sales of NVIDIA’s Blackwell processors, launched in May, rose 17 percent quarter-on-quarter. The product line has quickly become the backbone of NVIDIA’s data center business, accounting for a majority of the segment’s revenue.

Wall Street reacts to NVIDIA results

Despite NVIDIA’s strong numbers, company shares initially slipped in after-hours trading as some investors fretted about slower growth momentum in the data center division.

Regardless, the stock later pared its losses by turning positive on Thursday (August 28).

Overall, NVIDIA has surged 35 percent so far this year after nearly tripling in 2024.

NVIDIA performance, August 25 to 28, 2025.

Chart via Google Finance.

The company is guiding for revenue of US$54 billion, plus or minus 2 percent, in the October quarter.

However, that forecast does not assume any shipments of the H20, a chip that was designed for the Chinese market, but is currently sidelined by export restrictions.

Colette Kress, NVIDIA’s CFO, told analysts the company could ship between US$2 billion and US$5 billion worth of H20 processors this quarter if geopolitical conditions allow.

No H20 sales to China

NVIDIA confirmed it had no H20 sales to China in its second quarter.

Instead, it benefited from releasing US$180 million in previously reserved H20 inventory to a customer outside of China, boosting reported revenue by US$650 million. The company previously said that the lack of H20 shipments cost it up to US$8 billion in potential sales in the second quarter alone.

Huang met with US President Donald Trump earlier this summer to lobby for licenses to export the H20, a chip that was developed specifically to comply with US trade restrictions.

Under a tentative deal, NVIDIA agreed to pay 15 percent of China H20 revenue to the US government in exchange for export approvals. However, the arrangement has yet to be codified into a formal agreement.

Blackwell and the China dilemma

Beyond H20, attention has shifted to NVIDIA’s newest flagship processor, Blackwell.

On Wednesday’s (August 27) earnings call, Huang said there is “a real possibility” of bringing Blackwell to China.

“We just have to keep advocating the importance of American tech companies to be able to lead and win the AI race, and help make the American tech stack the global standard,” he said. Huang estimates that China represents a US$50 billion opportunity for NVIDIA this year, with growth of 50 percent annually. He argued it is better for Chinese AI firms to use NVIDIA chips, even if modified, rather than being forced to rely on domestic alternatives.

Trump, however, has expressed caution. Speaking at a press conference earlier this month, he said, “The Blackwell is super-duper advanced. I wouldn’t make a deal with that.”

However, he said he could allow a “somewhat enhanced in a negative way” Blackwell chip to be sold to China, further suggesting that such a version could be slowed by 30 to 50 percent to comply with US restrictions.

Even without China sales, NVIDIA maintains a bright outlook.

Huang told analysts the buildout of AI infrastructure is still in its early stages, further projecting that global spending on AI infrastructure could reach US$3 trillion to US$4 trillion by the end of the decade.

Furthermore, large cloud providers, which remain NVIDIA’s biggest customers, have announced plans to spend tens of billions of dollars per quarter on AI infrastructure, ensuring a steady pipeline of demand for the company’s chips.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

Billionaire-backed KoBold Metals Secures DRC Licenses in Push for Manono Lithium

KoBold Metals, a US-backed mining firm supported by billionaires Jeff Bezos and Bill Gates, has received seven new permits to explore for lithium in the Democratic Republic of Congo (DRC).

The DRC mining registry confirmed on Wednesday (August 27) that the permits cover ground in both the Tanganyika and Haut-Lomami provinces, including four in Manono territory, home to the massive Roche Dure lithium deposit.

The approvals follow a July agreement between KoBold and the DRC government that positioned the company to acquire and develop the disputed Manono project, considered one of world’s largest untapped lithium deposits.

“Our exploration efforts across all seven new licenses will be focused on lithium,” a KoBold official told Reuters. The permits also authorize searches for coltan, rare earths and other minerals across more than a dozen prospective sites.

For the DRC, the deal with KoBold furthers its strategy to attract western capital and technology to its critical minerals sector, reducing reliance on Chinese firms that dominate much of the country’s cobalt and copper production.

President Félix Tshisekedi publicly endorsed the agreement in July, framing it as a cornerstone of the DRC’s ambitions to strengthen its role in global electric vehicle supply chains.

Betting on AI-driven exploration

Founded in 2018 and backed by Breakthrough Energy Ventures, KoBold counts Bezos, Gates and venture firm Andreessen Horowitz among its investors. The company touts its use of artificial intelligence (AI) and advanced computing technology to accelerate the search for copper, cobalt, nickel and lithium.

Under its July framework with Kinshasa, California-based KoBold committed to launching a large-scale exploration program across more than 1,600 square kilometers by mid-2025. The agreement also obliges the DRC to appoint a special envoy to facilitate KoBold’s pursuit of the Manono acquisition.

In addition to field exploration, the company has pledged to digitize geological records housed at Belgium’s Royal Museum of Central Africa and make them publicly accessible through the DRC’s National Geological Service.

Legal clouds over Manono

Despite KoBold’s focus on Manono, the asset is mired in a protracted legal battle.

AVZ Minerals (ASX:AVZ), through its local joint venture Dathcom Mining, argues that it remains the rightful permit holder and has taken its case to the International Center for Settlement of Investment Disputes.

Last year, the tribunal issued interim measures ordering the DRC to recognize AVZ’s rights pending a final ruling.

AVZ said the KoBold agreement, which covers parts of the same perimeter, breaches those orders.

In a July 21 statement, the company stressed that it “remains open to constructive dialogue,” but insisted that any outcome must respect its legal rights and existing relationships.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

Can You Invest in Neuralink?

Elon Musk’s Neuralink has captured the public’s attention and imagination with its futuristic vision of connecting the human brain to computers.

A July 2024 report by IDTechEx projects that the overall brain computer interface (BCI) market could reach a market value of over US$1.6 billion by 2045.

‘We anticipate that the market for non-invasive solutions will grow before the commercialization of invasive solutions from players such as Neuralink,’ stated the research firm’s Senior Technology Analyst Dr. Tess Skyrme. ‘However, the long-term opportunity within the assistive technology market is more likely to be captured by the likes of Elon Musk.’

As Neuralink continues to make strides, investors are wondering how to get a piece of the action by investing in the neurotechnology venture.

Because it is privately held, Neuralink stock isn’t accessible to the average person — but that doesn’t mean its impossible to get exposure to this future-looking medical research company. Read on to learn how to participate in the growth of this exciting business.

In this article

    What is Neuralink?

    Neuralink is a neurotechnology startup that was founded in 2016 by Tesla (NASDAQ:TSLA) CEO Musk and a team of eight scientists and engineers in 2016.

    It was first reported on in 2017, and two years later, in June 2019, the company held and streamed its public launch event to showcase the technology it is developing: an innovative brain-computer interface.

    Instead of using traditional electrodes, which according to a company whitepaper can be bulky and damaging to brain tissue, Neuralink’s BCI uses “ultra-thin threads” that are implanted into the brain using a robotic device that resembles a sewing machine. Once implanted, the electrodes develop a BCI, stimulating the brain and monitoring activity, and the threads connect to a custom-designed chip that can read data from groups of neurons.

    Potential uses of BCI technology include helping paralyzed individuals regain control of their limbs and restoring vision. Musk told his audience during Neuralink’s 2019 launch event that this technology could have a wide range of applications in medicine, such as restoring sensory and motor function in people with spinal cord injuries or neurological disorders. Additionally, an early goal of development is translating neuron signals into computer commands, which would allow humans to control devices like computers and smartphones with their brainwaves.

    Musk has claimed that BCI could even facilitate direct communication between humans and machines, although some members of the neuroscientific community are skeptical. Other experts have suggested that Neuralink’s work is not necessarily novel — as Dr. Jason Shepherd, an associate professor of neurobiology at the University of Utah, told Business Insider in 2020, “All the technology that he showed has been already developed in some way or form. Essentially what they’ve done is just package it into a nice little form that then sends data wirelessly.”

    Other experts in the field have ethical concerns about how Neuralink is conducting its clinical trials and the broader implications of disregarding established standards.

    “If you decide to play with fire in a house, you increase the risk threshold not only of yourself but of the whole house,” Marcello Ienca, a professor of ethics of AI and neuroscience at Technical University of Munich, told Forbes. “My fear is that Neuralink’s disregard for the ethical aspects of their technology may cause a backfire effect for the entire neurotechnology community.”

    How much is Neuralink worth?

    Neuralink was reportedly valued at around US$9 billion in May 2025, but as a privately held business, much of its financial information is kept under wraps. That said, US Securities and Exchange Commission (SEC) documents containing information about its funding rounds provide some insight.

    The earliest came in 2017, when the company raised US$27 million out of a planned US$100 million in a Series A funding round. In April 2019, SEC filings show the company acquired US$39 million out of a planned US$51 million in a Series B funding round. A limited amount of information has been made available to the public, and the identities of the investors have not been publicly disclosed. However, some news outlets have speculated that funding could have come from a combination of venture capitalists, or from Musk himself and the Neuralink team.

    In 2021, Neuralink received what was then its largest amount of money to date, raising US$205 million in a funding round led by tech investment firm Vy Capital. Other participants included Google Ventures, the venture capital arm of Alphabet (NASDAQ:GOOGL); OpenAI CEO Sam Altman; Fred Ehrsam, co-founder of Paradigm and Coinbase Global (NASDAQ:COIN); and Ken Howery, co-founder of PayPal Holdings (NASDAQ:PYPL) and Founders Fund.

    In May 2023, as Neuralink faced public backlash over accusations of animal mistreatment, it received clearance from the US Food and Drug Administration (FDA) to run the first human trial of its brain implant. Just months later, in August, Neuralink closed a US$280 million funding round led by Founders Fund. The filing was amended in November 2023 to reflect an additional US$43 million, bringing the total to US$323 million.

    Most recently, the company announced the closure of a US$650 million Series E funding round in June 2025.

    Is Neuralink approved for human trials?

    In May 2023, the US Food and Drug Administration granted Neuralink clearance to run the first human trials of its brain implant, and Health Canada approved Neuralink brain-computer implant clinical trials in November 2024.

    During the company’s summer update meeting in July 2025, it was revealed that a total of nine human clinical trial participants have received the Neuralink implant. A subsequent study was launched in Great Britain in July 2025, and the company said it will soon begin a trial to help restore sight to the blind in the United Arab Emirates.

    Neuralink has so far made the most progress with its US clinical trial. The company opened a patient registry in early 2023 that allowed people who had at least one of a qualifying list of conditions to volunteer for upcoming clinical trials.

    The first study, dubbed PRIME — Precise Robotically Implanted Brain-Computer Interface — is specifically focused on patients with cervical spinal cord injuries or amyotrophic lateral sclerosis. It has an estimated primary completion date of January 2026 and is estimated to be fully completed by January 2031.

    Musk said in January 2024 that the brain chip being used for testing is named Telepathy. It is about the size of a coin, and each one is equipped with over 1,000 electrodes 20 times finer than human hair that fan out into the cerebral cortex. The first operation was performed on January 29, 2025. Musk shared the results on X, formerly known as Twitter, stating that the patient was “recovering well” and that “initial results show promising neuron spike detection.”

    The next update came during a Spaces event on X on February 19, 2024, during which Musk stated that the patient had recovered and was able to move a computer cursor using thought. In mid-May, Neuralink’s first patient, Noland Arbaugh, who is quadriplegic, shared his experiences in his first 100 days with the Neuralink brainchip.

    According to Arbaugh at the time, despite some setbacks, he believed his trial to be a success. One of the largest benefits was that the Link allowed him to operate his computer and other devices lying down, while he needed assistance for setup and repositioning with prior devices. This gives him more freedom to live on his own time, he explained. Additionally, it offers greater control than other devices he has used.

    ‘The games I can play now are leaps and bounds better than previous ones,’ Arbaugh said. ‘I’m beating my friends in games that as a quadriplegic I should not be beating them in.’

    Reuters reported in May 2024 that Neuralink would enroll another three patients in its clinical trial. The company has since implanted a brain chip into two additional patients, one who became paralyzed following a spinal cord injury from a diving accident and another who lost use of his limbs to amyotrophic lateral sclerosis (ALS). The company issued an update on their progress in February 2025, with all three patients touting positive changes following the procedure.

    How to invest in Neuralink?

    With Neuralink continuing to move forward, how can investors get a piece of this up-and-coming technology?

    As mentioned, the firm has yet to go public, so purchasing Neuralink stock is not an option for many investors. The vast majority of Neuralink’s funding has come from venture capitalists and a handful of billion-dollar companies.

    However, there are still ways for investors to potentially profit from Neuralink’s growth before it goes public. For example, investing in publicly traded companies that have invested in Neuralink can provide an indirect stake. Many of the company’s investors are venture capital firms or private individuals, but some of these firms, such as Google Ventures, are subsidiaries of publicly traded companies. By investing in Alphabet, individuals can indirectly benefit from its investment in Neuralink, as any profit from the investment could potentially flow back to Alphabet.

    This indirect approach can be a viable strategy for individuals who want to gain exposure to Neuralink without waiting for the company to go public. Coinbase is another company that offers indirect exposure to Neuralink’s growth; the enterprise is owned by Ehrsam, whose venture capital fund Paradigm has invested in Neuralink.

    Those who qualify as accredited investors could also potentially invest in a Neuralink funding round. According to the SEC, an accredited investor must have a net worth of at least US$1 million, not including the value of their primary residence, or an annual income of at least US$200,000 for individuals and US$300,000 for married couples. There must also be a reasonable expectation of the same level of income in the year of filing.

    Individuals can also qualify as accredited investors if they are investment professionals in good standing. In that case, the SEC’s guidelines indicate that they need to hold either a general securities representative license, an investment advisor representative license or a private securities offerings representative license.

    Entities like banks, insurance companies or investment firms with total assets of at least US$5 million may also qualify as accredited investors. Certain types of entities, such as private business companies and small business investment companies, may be exempt from the standard asset value requirements for accredited investor status.

    It’s also worth noting that Neuralink is just one of several companies currently working on developing BCI technology. According to research by IDTechEx, companies working to develop invasive brain-computer interface solutions have amassed nearly US$1.5 billion in funding.

    One competitor is Synchron, a company with similar ambitions that has received funding from the likes of Jeff Bezos and Bill Gates. On February 1, 2024, Synchron acquired a minority stake in German manufacturer Acquandas. This acquisition secures exclusive access to Acquandas’ advanced metal layering technology, which is a critical component for Synchron’s device, the Synchron Switch.

    Synchron launched a patient registry in April 2024 to prepare for an upcoming large-scale brain implant trial required to apply for US Federal Drug Administration (FDA) medical device approval. In July, the company announced that one of the patients implanted with the Synchron BCI was able to use his direct thoughts to control the cursor on the Apple Vision Pro. A year later, Synchron publicly demonstrated the first-ever use of a thought-controlled iPad, using Apple’s BCI Human Interface Device (BCI HID) input protocol that allows a person to control the device with just their thoughts.

    Earlier this year Synchron announced a partnership blending NVIDIA’s (NASDAQ:NVDA) Holoscan platform with its BCI technology. “Synchron’s vision is to scale neurotechnology to empower humans to connect to the world, and the NVIDIA Holoscan platform provides the ideal foundation,” Synchron CEO and Founder Tom Oxley stated.

    The company has since revealed that its implantable BCI is now powered by Chiral AI, a proprietary foundation model of cognition that is trained directly on neural data. This allows its system to move from simple intent recognition to more advanced, self-learning cognitive AI.

    Precision Neuroscience is another company working in the brain-computer interface field, although it is also private. Founded by one of Neuralink’s co-founders, the BCI company is currently testing its Layer 7 Cortical Interface, which is a thin, flexible film that sits on a brain’s gray matter instead of being implanted in it, making it less invasive.

    Precision Neuroscience recently set a record for the highest number of electrodes used to detect a person’s thoughts at 4,096 when they combined four of their interfaces on one brain. The company completed a funding round of US$102 million in December 2024.

    In April 2025, Precision Neuroscience received 510(k) clearance from the FDA for its Layer 7 Cortical Interface, authorizing it for commercial use for up to 30 days. This clearance allows the company to use its technology for intraoperative brain mapping and to build a large repository of neural data.

    A newer market entrant, Merge Labs, is set to receive funding at a US$850 million valuation from OpenAI. Sam Altman will reportedly be a co-founder, according to a report from The Financial Times.

    Although the field is nascent, the potential for BCI to impact various industries such as robotics, medicine and biotech has generated a growing amount of interest and excitement. Additionally, heightened interest in the artificial intelligence (AI) sector has led to more research and exploration in related fields, and has attracted increased investment in fields benefiting from AI advancements, including robotics and medicine.

    AI is also being used as a tool to help discover new insights and make moves that might not have been possible without its use. Scientists in California have even developed a brain implant capable of decoding and vocalising inner speech.

    Finally, one of the simplest ways to gain exposure to Neuralink would be through an exchange-traded fund (ETF) that invests in companies related to BCI technology. While there isn’t an ETF that exclusively focuses on BCIs, there are funds that offer exposure to related themes. One example is the iShares Healthcare Innovation ETF (LSE:HEAL,OTC Pink:BLKIF). This fund consists of companies that are developing new and innovative healthcare technologies.

    Two other options are the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ), which includes companies that are involved in the development of robotics and AI, and the ARK Innovation ETF (ARCA:ARKK), which focuses on disruptive technologies across multiple industries, including healthcare and robotics.

    As with any investment decision, it’s important to perform due diligence on available options, including comparing ETFs, to ensure they align with one’s investment goals.

    Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    Keep Reading
    Investing

    How to Invest in Gene Stocks and ETFs

    Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on through generations. So what is genetics investing?

    When it comes to genetics investing, companies in this niche of the life science sector are mostly focused on four submarkets: DNA sequencing, genetic testing, gene therapy and genomics, which includes gene editing.

    This life sciences submarket has gained much attention from investors over the past several years. It has provided a launching pad for a number of biotech firms developing and commercializing novel treatments and drugs addressing a wide range of diseases with unmet needs.

    For those looking to dive into the genetics sector, there are numerous investment opportunities to consider. Investing in gene stocks is the most common route, but there are risks due to the market’s volatility, especially when it comes to wins or losses with the US Food and Drug Administration (FDA).

    Exchange-traded funds (ETFs) are another popular option for gaining exposure to the industry, and come with less risk than investing in a single stock.

    In this article

      What are the key areas of the genetics sector?

      Before diving into investment opportunities in the genetics market, it’s important to understand the industry and the key areas of genetics mentioned above.

        What investors should know about the genetics market

        In the biotech sector, gene therapy is one of the more advanced treatment options, and gene therapy pipeline candidates are robust in late-stage clinical trials.

        In terms of what will — and already has — disrupted the genetics industry, CRISPR gene-editing technology has been on the rise for quite some time. It uses short repeating DNA sequences with “spacers” dividing them to treat genetic diseases.

        While the use of the technology is still in its early stages, in the coming years it’s expected to have a big impact on how genetic diseases are treated, and there are a range of clinical trials underway involving CRISPR technology. So far, the only FDA approved CRISPR-based medicine is Casgevy, developed by Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP). It was originally approved in late 2023 for the treatment of sickle cell disease.

        The prominence of gene therapies in the life science sector was a major theme at the 2025 JPMorgan Healthcare Conference in January 2025. Peter Marks, then-director of the FDA’s Center for Biological Evaluation and Research, told attendees that his agency is aiming to accelerate approvals for gene therapies.

        In 2024, the FDA expanded approvals for CRISPR-based Casgevy to beta-thalassemia, and it also approved Pfizer’s (NYSE:PFE) Beqvez and PTC Therapeutics’ (NASDAQ:PTC) Kebilidi.

        Despite experiencing a challenging year in 2024, there is still a lot of optimism in the gene therapy sector. Also speaking at the January conference, Alliance for Regenerative Medicine president Tim Hunt said he believes 10 new cell and gene therapy treatments could reach blockbuster status by 2030.

        “No one’s saying there aren’t headwinds, but we are seeing important signs of growth,” he added.

        Looking at DNA sequencing, this market is driven by advances in biotech, the increasing prevalence of cancer and rising demand for precision medicine, as well as higher investment in research and development. DNA sequencing has become a vital component of this growth and has played a key role in remodeling molecular biology and genomics research.

        Genetic testing is another segment of the genetics industry that is growing at a fast pace. Unsurprisingly, technological breakthroughs have had a huge impact on genetic testing, and so has the fact that governments and regulatory bodies are turning their attention to this market in order to regulate and raise awareness to treat diseases such as cancer, cystic fibrosis and sickle cell anemia.

        Biotech and pharmaceutical companies are also expressing interest in this sector, which is expected to further fuel genetics sector growth in the coming years. Mergers and acquisitions activity is also expected to increase as companies seek to expand their product portfolios new candidates and technologies.

        As can be seen, the genetics industry is vast and complex, but is also ripe with investment opportunities.

        How to invest in gene stocks

        Investors looking to invest in the field of genetics through stocks have many options, from large-cap biotech companies to pure-play gene therapy, gene editing and genetic testing stocks.

        See the list below for genetics companies to consider, and check out the linked stock lists for more options.

        Large-cap gene stocks

        There are a number of large-cap biotech companies that have significant focuses on the field of genomics. Here are a few to consider:

        Amgen (NASDAQ:AMGN)
        A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. The company’s subsidiary deCODE Genetics is researching how human genetic diversity influences disease.

        AbbVie (NYSE:ABBV)
        Research-based global biopharmaceutical company AbbVie that addresses several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology. AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapeutics, viewed as a promising genetic medicine approach for silencing disease-causing genes.

        Regeneron Pharmaceuticals (NASDAQ:REGN)
        Regeneron Pharmaceuticals creates medicines for a wide variety of diseases. The Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts in collaboration with health organizations around the world.

        Gene editing (CRISPR) stocks

        There are a variety of options for investors looking to buy in on the field of gene editing stocks, including:

        CRISPR Therapeutics (NASDAQ:CRSP)
        CRISPR Therapeutics and its partner Vertex Pharmaceuticals co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market, as well as by the European Medicines Agency and Health Canada.

        Intellia Therapeutics (NASDAQ:NTLA)
        Intellia Therapeutics is a gene editing biotech company developing drugs for patients with genetic and autoimmune diseases. The company’s drug pipeline includes late-stage clinical programs for therapies targeting hereditary angioedema and transthyretin amyloidosis.

        Vertex Pharmaceuticals (NASDAQ:VRTX)
        Vertex Pharmaceuticals is the other half of the team behind Casgevy. It also offers exposure to other sectors of genomics, with approved treatments for cystic fibrosis and a pipeline of genetic and cell therapies. Its investigational VX-880 islet cell replacement therapy could restore insulin production in patients with type 1 diabetes.

        Gene therapy stocks

        Gene therapy stocks and stem cell stocks are also popular choices for genetics investing. Here are a few to get you started:

        Novartis (NYSE:NVS)
        Switzerland-based Novartis is focused on treatments for a wide range of diseases, including cancers, malaria, leprosy and sickle cell disease. Novartis is developing adeno-associated-virus (AAV)-based and CRISPR-based gene therapies. Its Kymriah treatment was the first CAR-T cell therapy to be approved by the FDA, and the agency also approved its AAV-based therapy Zolgensma.

        Gilead Sciences (NASDAQ:GILD)
        Global biopharmaceutical company Gilead Sciences is advancing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. Its cell-based gene medicine for blood cancer, the CAR T-cell therapy Yescarta, was the second gene therapy approved by FDA.

        uniQure (NASDAQ:QURE)
        Genomic medicine company uniQure develops and markets gene therapy products for patients with severe genetic diseases. The company’s AAV-based gene therapy platform targets liver-directed and central nervous system disorders.

        Genetic testing stocks

        For those interested in genetic testing stocks, these three stocks provide a snapshot on different ways to get exposure to the sector:

        Exact Sciences (NASDAQ:EXAS)
        Exact Sciences focuses on molecular diagnostic tests. The company has developed a molecular screening technology platform called Cologuard that detects a range of cancers, including breast cancer and colorectal cancer.

        Fulgent Genetics (NASDAQ:FLGT)
        A leader in clinical diagnostic genetic sequencing, Fulgent Genetics is a full-service genomics testing company. Its proprietary technology platform, Picture Genetics, allows for the identification of personal DNA health markers in individual patients.

        Illumina (NASDAQ:ILMN)
        Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. Its focus is on oncology testing, genetic disease testing, reproductive health and research.

        How to invest in genomics ETFs

        For those who would prefer to invest in the genetics industry overall rather than buying shares in an individual gene stock, investing in genomics ETFs is the way to go. Here are some available ETFs that offer exposure to companies in the biotech and genetics sectors to start you off:

        ARK Genomic Revolution ETF (ARCA:ARKG)
        This ETF tracks firms focused on CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Its holdings include CRISPR Therapeutics and Guardant Health (NASDAQ:GH).

        Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
        The Global X Genomics & Biotechnology ETF invests in stocks that are involved in genomic science, which includes gene computational genomics and biotechnology. Its holdings include Illumina and Avidity Biosciences (NASDAQ:RNA).

        iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)
        The iShares Genomics Immunology and Healthcare ETF focuses on companies involved with genomics, immunology and bioengineering. Its holdings include Regeneron Pharmaceuticals and Arcellx (NASDAQ:ACLX).

        Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

        This post appeared first on investingnews.com

        Keep Reading